Forgot your password?

Forgot your username?

database > company
Ligand Pharmaceuticals
Biotech Specialty Pharma
10275 Science Center Drive
San Diego, CA 92121 USA
phone:1 858 550-7500
fax:1 858 550-7506
Symbol LGND
Exchange NASDAQ
Founded 0
Employees
www.ligand.com
Research Sector Biotech Specialty Pharma
Summary Description
New drugs that address critical unmet medical needs.
Management
John L. Higgins, President and CEO; Martin D. Meglasson, PhD, Vice President, Discovery Research; Zofia E. Dziewanowska, MD, PhD, Vice President, Clinical Research; Syed Kazmi, PhD, MBA, Vice President, Business Development and Strategic Planning; John P. Sharp, Vice President, Finance and CFO; Charles Berkman, JD, Vice President, General Counsel and Secretary
Ownership
Financials Mkt Cap :1


* numbers in thousands
 

Keywords
oncology, cancer, dermatology, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular, inflammatory diseases, gene transcription technology

Comment | Printable Version | Modify profile |
Updated: Oct. 04, 2011

Description
Ligand Pharmaceuticals, Inc. discovers, develops and markets small molecule drugs to address critical, unmet medical needs.
Products / Services
Ligand markets four oncology and dermatology products in the United States ' ONTAK, Targretin capsules, Targretin gel and Panretin gel. Ligand's fifth and newest product, AVINZA, is a treatment for chronic, moderate-to-severe pain.
Technology / Differentiation
Ligand produced a diverse portfolio of technologies and assets across numerous therapeutic areas, drug targets, and industry partners. They offer investors an opportunity to spread their risk while investing in the increasingly complicated and unpredictable pharmaceutical industry.
Status
Ligand's network of major pharmaceutical partners is developing products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's robust R&D pipeline is based on the company's leadership in gene transcription technology.


2012-05-21-857